The collaboration is focused on the development of a new generation of steroids and steroids related pharmaceuticals for rapid subcutaneous absorption.
PharmaNova’s NovaSperse nanoparticle technology will be leveraged to enhance the aqueous dissolution of lipid soluble drugs thus facilitating the administration using Eternity Healthcare’s Comfort-In needle-free injection system.
Under the terms of the deal, both companies will equally share the financing of the product development and the revenue.
Further details and commercial structure will become available in the final agreement that is expected to be completed by 30 September 2013.